Navigation Links
Experimental Drug May Cut Severe Asthma Attacks: Study
Date:8/17/2012

By Steven Reinberg
HealthDay Reporter

THURSDAY, Aug. 16 (HealthDay News) -- An experimental drug known as mepolizumab may reduce outbreaks by almost 50 percent in people with a type of hard-to-treat asthma, an early study finds.

About a third of people with severe asthma have what is called eosinophilic asthma, in which inflammatory cells called eosinophils cause swelling of lung airways. Standard asthma treatment with inhaled steroids isn't effective, so these patients take oral steroids, which have many side effects, the researchers explained.

Mepolizumab blocks the production of eosinophils and reduces the frequency of severe asthma outbreaks, which may reduce the need for steroids, the researchers said.

The new drug is a monoclonal antibody, a class of drugs involving naturally occurring human antibodies that are genetically altered in a laboratory, cloned in large numbers and introduced into the patient to target disease sites.

"This is a promising new drug treatment," said lead researcher Dr. Ian Pavord, a consultant physician at the University Hospitals of Leicester NHS Trust, in England. "I think it's going to become a viable treatment and it offers hope to a group of people that are having really big problems with their asthma."

The purpose of this trial was to find out the best dose of the drug and to identify the type of patients most likely to benefit from it, Pavord said.

"It's been a successful study, because we have established the drug is effective even in low doses and patients can be identified through a blood test," Pavord said.

Some patients taking mepolizumab may be able to reduce the amount of steroids they take, Pavord said.

"If that were the case it would be very attractive to the patient," he said.

GlaxoSmithKline, the maker of mepolizumab, funded the trial. The findings were published Aug. 16 in the online edition of the journal The Lancet.

For the study, Pavord's team randomly assigned more than 600 patients with severe asthma to receive one of three doses of mepolizumab or a placebo. The drug is given intravenously once a month. Participants included asthma patients from 81 medical centers in 13 countries, and their ages ranged from 12 to 74 years old.

After a year, the researchers found that patients taking mepolizumab had about half the number of severe outbreaks requiring ER visits or hospitalizations as patients taking a placebo. Patients taking mepolizumab also had half as many outbreaks that required oral steroids.

Although mepolizumab effectively reduced outbreaks, it didn't produce consistent improvements in symptoms or lung function, the study found. "It's not a cure," Pavord said. "It's likely to be a long-term treatment."

Headaches and swelling of the nasal passages were seen among patients taking the drug and those on placebo, the researchers noted. Side effects from oral steroids include mood changes, increased appetite, weight gain and acne.

Although three patients died during the study, their deaths were deemed to be unrelated to the treatment.

Since the drug is still experimental and phase 3 trials are just getting under way, the potential cost of the drug, if approved, isn't known. Approval of mepolizumab for asthma isn't expected for at least three to four years, Pavord said.

"The results of this study are very impressive," said Dr. Rubin Cohen, director of the Asthma Center at North Shore-LIJ Health System in New Hyde Park, N.Y.

He said the drug could be very helpful for patients with the most severe type of asthma that can't be controlled with inhaled steroids.

"If this pans out, these asthmatics would have a different treatment option and be able to control their asthma without the side effects of steroids," he said. "They may actually be able to get off steroids completely or reduce the amount of steroids they take substantially."

More information

To learn more about asthma, visit the U.S. National Library of Medicine.

SOURCES: Ian Pavord, M.B., consultant physician, University Hospitals of Leicester NHS Trust, England; Rubin Cohen, M.D., director, Asthma Center, North Shore-LIJ Health System, New Hyde Park, N.Y.; Aug. 18, 2012, The Lancet, online


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Drug Suppresses Appetite in Mice: Study
2. Experimental Chemical Helps Blind Mice See
3. Experimental drug may extend therapeutic window for stroke
4. Fertility preservation with cryopreservation of ovarian tissue: from experimental to mainstream
5. Content Writing King Announces Cancellation Of Experimental Video Creation Process For Their Article Marketing Website
6. Experimental Vaccine Seems to Stop Nicotine Addiction in Mice
7. Experimental drug improves muscle strength among male cancer patients
8. Experimental Drug Helps Fight Some Childhood Cancers, Study Finds
9. Experimental Drug Eases Autistic Behaviors in Mice
10. Experimental Gel May Help Those With Advanced Parkinsons
11. Experimental Pill for Multiple Sclerosis Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug May Cut Severe Asthma Attacks: Study
(Date:3/22/2017)... Valhalla, New York (PRWEB) , ... March 22, ... ... Blythedale Children’s Hospital have entered into a research collaboration to translate advances in ... with neurological impairments at Blythedale and beyond. The collaboration seeks to improve movement, vision, ...
(Date:3/22/2017)... ... March 22, 2017 , ... SNL Insurance ... to families and business owners in the greater Hampton Roads area, is embarking ... Society Relay For Life event. , Each year, hundreds of people living in ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... Schneider Insurance ... families and business owners throughout the Yellowstone Valley region, is launching a charity event ... zoo and botanical garden in all of Montana State, and is home to a ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... College basketball ... Self still makes time for recruiting – that is, recruiting people to be foster ... and homes to children who are in foster care due to abuse, neglect and ...
(Date:3/22/2017)... ... ... NYC Chiropractor Dr. Steven Shoshany recently helped host a seminar at his cutting ... and focused on a new protocol for treating pain. Dr. Shoshany is among the ... furthermore the first seminar in the country was hosted at his Integrated Chiropractic Practice. ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , 22. März 2017   ... und weltweit tätige Anbieter von Produkten und ... den Erwerb von EPL Archives Inc. bekannt, ... der Kunden im kompletten Zyklus regulierter Forschung, ... von Proben, Speicherung von Dokumenten und Zusatzdienstleistungen ...
(Date:3/22/2017)... 22, 2017  Applied BioMath ( www.appliedbiomath.com ), ... research and development, today announced the latest line-up ... 2017 is a day full of presentations, posters, ... (QSP) community. The focus is to learn about ... accelerating drug research and development. The ...
(Date:3/22/2017)... March 22, 2017 National Medical Products ... received an Innovative Technology contract from Vizient, ... in the country. The contract was based on ... with expertise in this category who serve on ... Technology contracts for technologies that demonstrate an ability ...
Breaking Medicine Technology: